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Abstract 
The goal of biomarker research is to identify clinically valid markers. Despite decades of research there has been disap‑
pointingly few molecules or techniques that are in use today. The “1st International NTNU Symposium on Current 
and Future Clinical Biomarkers of Cancer: Innovation and Implementation”, was held June 16th and 17th 2016, at the 
Knowledge Center of the St. Olavs Hospital in Trondheim, Norway, under the auspices of the Norwegian University of 
Science and Technology (NTNU) and the HUNT biobank and research center. The Symposium attracted approximately 
100 attendees and invited speakers from 12 countries and 4 continents. In this Symposium original research and over‑
views on diagnostic, predictive and prognostic cancer biomarkers in serum, plasma, urine, pleural fluid and tumor, 
circulating tumor cells and bioinformatics as well as how to implement biomarkers in clinical trials were presented. 
Senior researchers and young investigators presented, reviewed and vividly discussed important new developments 
in the field of clinical biomarkers of cancer, with the goal of accelerating biomarker research and implementation. 
The excerpts of this symposium aim to give a cutting‑edge overview and insight on some highly important aspects 
of clinical cancer biomarkers to‑date to connect molecular innovation with clinical implementation to eventually 
improve patient care.
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Background
The “1st international NTNU symposium on current 
and future clinical biomarkers of cancer: innovation and 
implementation”, was held June 16th and 17th 2016, at the 
knowledge center of the St. Olavs Hospital in Trondheim, 
Norway, under the auspices of the Norwegian University 
of Science and Technology (NTNU) and the HUNT 
biobank and research center. The Symposium attracted 
approximately 100 attendees and invited speakers from 
12 countries and 4 continents. Senior researchers and 
young investigators presented, reviewed and vividly dis-
cussed important new developments in the field of clini-
cal biomarkers of cancer, with the goal of accelerating 
biomarker research and implementation.
Inspiration for arranging this Symposium in Trond-
heim came from worldwide rapid developments in 
the biomarker field and current research based on the 
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Norwegian Nord-Trøndelag Health Study (HUNT), a 
population study founded in 1986 that has evolved to 
become a Biobank and Research Center under the NTNU 
(http://www.mensxmachina.org/cancer_biomarker_
hunt/index.html). The center is situated in Levanger and 
houses hundreds of clinical data variables, serum and 
DNA from about 120,000 people that are accessible for 
researchers. The meeting highlighted the unique poten-
tial and growing network around this resource, as well as 
the necessity of discussing clinical cancer biomarkers and 
their implementation in a broad forum.
The Symposium served to remind us that cancer is a 
collection of very heterogeneous diseases, making molec-
ular sub grouping increasingly relevant for diagnosis and 
treatment. Since the discovery of the estrogen receptor in 
breast cancer, science has unraveled hundreds of clinically 
relevant diagnostic, prognostic, predictive and therapeu-
tic molecular markers of cancer, including HER2, KRAS, 
EGFR, ALK, BRAF, CTL4, PD1 and PD-L1, circulating 
tumor cells, protein and gene signatures, and microRNAs. 
New epigenetic and metabolic markers are also entering 
the stage, increasing the potential as well as the complex-
ity of targeted treatments for defined groups of cancer 
patients. However, few markers have passed all clinical 
development and validation phases and are actually in 
clinical use today. Following the initial discovery, the road 
taking a biomarker to clinical use is usually long and com-
plex. Moreover, clinicians should always be aware of cave-
ats that affect a biomarker’s broad applicability.
An iconic example is HER2/ERBB2 in breast cancer, 
initially discovered as a negative prognostic marker, it 
has now become a positive predictive marker due to the 
receptor’s “targetability” with trastuzumab, pertuzumab 
and other agents. This observation urges for the need for 
a set of accurate molecular diagnostic tests for each treat-
ment strategy. For example, the potential of the immune 
system to attack cancer cells using the PD1/PD-L1 inter-
action, one of the most important breakthroughs that 
change the cancer therapeutic algorithm in recent years. 
However, about one-third of the cases respond to anti-
PD1 monotherapy [1], and with the current cost of the 
treatment, picking the right patients will be of enormous 
value, not only for the patients but also the society. But 
are biomarkers for immune checkpoint therapy ready 
for use? Lastly, it is becoming apparent that detection of 
microRNAs or other molecules in circulation could be 
the first sign of early stage cancer, and could eventually 
become a blood test that saves thousands of lives. How 
far in the process are those tests? To reach the goals of 
true precision medicine and fulfill the Cancer Moon-
shot initiative [2] we need to valid these biomarkers and 
their accompanying diagnostic tests in the appropriate 
environment.
The excerpts of this symposium aim to give a cutting-
edge overview and insight on some highly important 
aspects of clinical cancer biomarkers to-date to connect 
molecular innovation with clinical implementation to 
eventually improve patient care.
Biomarkers in serum, plasma, urine and pleural 
fluid
Diagnostic, prognostic and predictive: catching all in one 
test, and how early?
More than half of all new lung cancer diagnoses are made 
in patients with locally advanced or metastatic disease, with 
few therapeutic options. However, screening efforts that 
use low-dose computed tomography (LDCT) are result-
ing in a greater proportion of lung cancers being diagnosed 
at an early, potentially curable, stage. Current guidelines 
for LDCT screening broadly include individuals based on 
age and history of heavy smoking. Biomarkers associated 
with lung cancer risk are needed to prioritize individu-
als for LDCT screening. LDCT detects a high number of 
nodules, of which fewer than 5 % are finally diagnosed as 
lung cancer. Thus, biomarkers are needed to help discrimi-
nate malignant nodules from benign or indolent lesions. In 
addition, prognostic biomarkers that molecularly catego-
rize early stage patients after tumor resection would help 
identify those high risk for recurrence would benefit from 
adjuvant chemotherapy or innovative immunotherapy. 
In “Integration of multiple “omic” biomarkers: a precision 
medicine strategy for lung cancer” Ana I. Robles, NIH/
National Cancer Institute, Bethesda, USA presented work 
on the identification of biomarkers in blood, urine, and 
resected tissues of early stage lung cancer patients. Elevated 
levels of pro-inflammatory cytokines IL-6, CRP and IL-8 
were associated with lung cancer diagnosis. Significantly, 
IL-8 levels were elevated up to 5  years before diagnosis, 
suggesting its potential use as part of a screening program 
[3]. Moreover, a combined IL-6 and IL-8 prognostic clas-
sifier was associated with poor outcome in stage I lung 
cancer patients, including those with  ≥30 pack-years of 
smoking (the relevant patient demographic targeted by 
LDCT screening) [4]. Using global and targeted metabo-
lomics they uncovered a set of urine metabolites associated 
with lung cancer diagnosis, which has now been validated 
in a prospective study, where metabolite levels are ele-
vated prior to clinically detectable disease [5, 6]. They also 
identified and validated prognostic biomarkers based on 
expression of genes and microRNA, and DNA promoter 
methylation in resected tissues [7–11]. Most recently, they 
integrated these biomarkers into a simple score that iden-
tified high-risk, therapy naive, stage I patients [11]. Cur-
rent efforts are focused on translating these biomarkers 
into clinical tests that can help address the unmet medical 
needs of early stage lung cancer patients (Fig. 1).
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Early diagnosis gets a new meaning when tumor-spe-
cific changes can be seen in the blood several years before 
clinical tumor is evident. Early pre-diagnostic tests may 
also change prognosis dramatically, as diagnosing lung 
cancer before reaching the size of 2 cm and before spread-
ing to the lymph nodes can confer a 5-year survival of 
80  %. In his talk “Serum microRNAs/enriched pathways 
in lung cancer 1–4 years before diagnosis—a pilot study 
from the HUNT Biobank, Norway”, Oluf D. Røe, Norwe-
gian University of Science and Technology, Trondheim, 
Norway, presented the work of his group aiming at dis-
covery of microRNAs, metabolites and proteins in serum 
samples 1–5  years before lung cancer diagnosis. Serum 
samples from the HUNT Biobank (https://www.ntnu.edu/
hunt/about-hunt), Levanger, Norway were profiled with 
separate total microRNA sequencing (Illumina). The sam-
ples included lung adenocarcinoma (n  =  4), squamous 
cell carcinoma (n = 5) and small-cell carcinoma (n = 5) 
cases collected 1–4 years before diagnosis, along with age 
and sex-matched non-cancer individuals (n  =  28), ratio 
1:2; the never smokers to ever-smokers ratio of controls 
was 50/50. The differentially expressed (DE) microRNAs 
were analyzed for enrichment by DIANA-miRPath v3. 0. 
The target genes of each microRNA included in the sig-
nature were determined with the DIANA-microT web 
server v5.0 and the union of all the microRNA targets 
was assessed for enrichment in KEGG pathways. Path-
ways with FDR-corrected p value  <0.05 are reported in 
the results. The preliminary results detected 12 DE micro-
RNAs in the adenocarcinomas plus squamous cell car-
cinomas versus controls as well as 9 DE microRNAs in 
small-cell carcinomas. Several pathways were enriched, 
including pathways for their respective cancer types 
(Table  1). They concluded that despite the small size of 
this pilot study, significantly DE microRNAs in serum 
of lung cancer patient were detected 1–4  years prior to 
diagnosis. These specific microRNAs also target cancer-
specific pathways. These preliminary results are currently 
validated in a larger cohort, hopefully resulting in a clini-
cal test in the near future.
How many years before a clinical diagnosis can a 
cancer signature be detected? In a large Norwegian 
study presented by Karina Standahl Olsen, Depart-
ment of Community Medicine, UiT The Artic Univer-
sity of Norway, Tromsø, Norway the answer was “Blood 
gene expression profiles reflect temporality and clinical 
parameters up to 6  years before breast cancer diagno-
sis—The Norwegian Women and Cancer Post-genome 
cohort (Kvinner og Kreft studien). Since the understand-
ing of time related aspects of systemic processes during 
carcinogenesis is very limited, this study aimed to iden-
tify time- and metastasis-related blood gene expression 
patterns present years before cancer diagnosis. Blood 
samples were collected prospectively from healthy, mid-
dle-aged women participating in the Norwegian Women 
and Cancer Post-genome cohort. Breast cancer cases 
Fig. 1 Biomarkers can help address the unmet needs of early stage lung cancer patients
Page 4 of 15Robles et al. J Transl Med  (2016) 14:295 
were identified via linkage to the Cancer Registry of Nor-
way, and matched controls were drawn from the cohort 
biobank. Full-blood gene expression was measured using 
Illumina Bead chips. The Cancer Registry provided infor-
mation on time of diagnosis relative to screening visits, 
and on lymph node status. The included 441 case–control 
pairs were ranked according to the time interval between 
blood sampling and cancer diagnosis, providing infor-
mation on blood gene expression up to six years before 
diagnosis. A non-parametric statistical method was 
developed to study changes in gene expression over time, 
named curve group analysis, which detects small gene 
expression differences that vary over time, and groups 
genes that display similar expression curves [12]. Blood 
gene expression differences between breast cancer cases 
and controls were dependent on time, and were strongest 
in the last year before diagnosis. Gene expression curves 
in the six years before diagnosis were only evident when 
stratifying cases according to mode of cancer detection 
and lymph node status. The study concludes that blood 
gene expression patterns do reflect clinical variability 
and temporality in the years before breast cancer diag-
nosis. These findings hold promise of increased insight 
into previously un-reachable aspects of systemic cancer 
biology. Blood gene expression patterns may be explored 
as potential biomarkers and/or used for development of 
tests [13].
In the presentation “The translational potential of cir-
culating tumor DNA in oncology”, Dana W.Y. Tsui, from 
the Department of Pathology and Center for Molecu-
lar Oncology, Memorial Sloan Kettering Cancer Center, 
New York, USA, gave an overview of the field and 
talked about the variety of clinical scenarios in which 
plasma DNA could be applied as a tool for noninvasive 
cancer management. This session outlined examples 
from different solid tumor, including breast, ovarian 
and lung cancers, to illustrate the application of cir-
culating tumor DNA profiling for molecular stratifica-
tion, monitoring tumor burden, identifying resistance 
mechanisms [14, 15]. The discussion also included an 
example from a research autopsy of a breast cancer 
patient to show that the analysis of circulating tumor 
DNA can reflect the dynamics of tumor clonal evolu-
tion from diagnosis to metastasis [15] The promise of 
circulating tumor DNA for detecting minimal residual 
disease, predicting prognosis and treatment response 
were illustrated in recent findings in breast and pros-
tate cancers [16, 17]. Noninvasive plasma profiling 
shows great promise for precision medicine and is 
gradually being introduced to the clinical setting. Prac-
tical considerations for the clinical implementation of 
plasma DNA profiling, including issues with pre-ana-
lytical factors such as the effects of sample process-
ing, as well as the requirement for clinical turn-around 
time, sample storage and informatics infrastructure, 
all need to be taken into consideration before effective 
clinical deployment (Fig. 2).
Decades of studies on circulating tumor cells (CTC) 
have shown promise, but still not found a place in the 
clinic, In his talk “Circulating Tumor Cells in early and 
recurrent breast cancer: Research and clinical applica-
tions” Vassilis Georgoulias, leading the research at the 
Department of Medical Oncology, School of Medicine, 
University of Crete, Greece reported data indicating that 
the detection of CTCs in patients with early stage breast 
cancer is an independent unfavorable prognostic factor 
for disease recurrence and disease-related death [18, 19] 
since CTCs cannot be eliminated by adjuvant chemo-
therapy or hormone treatment in almost 50  % of the 
patients, probably because of their non-proliferating and/
or dormant state. In addition, the measurement of CTCs 
in patients with metastatic disease (MBC) revealed that 
their increased number is associated with a decreased 
overall survival whereas numerous studies have reported 
that their decrease after one cycle of chemotherapy is 
associated with improved survival. Immunofluorescence 
studies have demonstrated that CTCs express phospho-
rylated EGFR (pEGFR) as well as HER2 (+) in 60–70 % of 
EBC patients, irrespective of the HER2 status of the pri-
mary tumor cells.
In a proof of principle study, pre-treated patients with 
MBC and pEGFR-expressing CTCs were treated with 
gefitinib, a specific tyrosine kinase inhibitor of the EGFR. 
A median reduction of 96.4 and 94.1  % in CTC count 
was observed in 11 of the 17 patients after one treat-
ment cycle; it is to note, that after the 3rd course, most 
detected CTCs were pEGFR (−). One patient achieved a 
partial response and in two patients the progression-free 
survival (PFS) was 16.0 and 19.0 months. Similar results 
were obtained with lapatinib, a dual EGFR and HER2 
tyrosine kinase inhibitor, as well as with trastuzumab, a 
monoclonal antibody against HER2. A randomized phase 
Table 1 MicroRNAs in  serum 1–4  years before  diagno-
sis of  lung cancer. Significantly differentially expressed 
microRNAs targeted genes of  several pathways that  were 
enriched, including  known pathways of  their respective 
cancer types
KEGG pathway P value #genes #miRNAs
SCLC vs controls
 ECM‑receptor interaction 7.85E‑31 25 4
 Small cell lung cancer 3.09E‑06 24 6
NSCLC vs controls
 Dopaminergic synapse 8.82E‑11 53 10
 Non‑small cell lung cancer 0.00142 17 10
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II study evaluating trastuzumab versus observation in 
women with HER2 (−) early breast cancer and detectable 
CTCs before and after adjuvant chemotherapy demon-
strated a significantly higher disease free survival (DFS) 
in the treated patients compared to those who received 
the standard treatment [19, 20]. These data support the 
phenotypic and biological characterization of CTCs pro-
viding valuable information regarding molecular targets 
that may lead to a more selected and individualized treat-
ment of patients with breast cancer.
Malignant mesothelioma is an asbestos-induced, 
aggressive tumor with limited treatment options and very 
poor outcome; median survival is less than 12  months 
and 5-year survival rates of between 5 and 10  % have 
been reported [21]. Development of mesothelioma-spe-
cific biomarkers is an active area of research aimed not 
only at enhancing clinical care but also providing a means 
to screen at-risk asbestos exposed populations for early 
intervention [22]. Soluble mesothelin is the most inten-
sively investigated mesothelioma biomarker and has been 
approved by the USA Food and Drug Administration as a 
tool for monitoring mesothelioma patient response and 
progression [23] The limited expression of the molecule 
on normal, nonmalignant tissue makes mesothelin an 
attractive therapeutic target as well as a diagnostic bio-
marker. Jenette Creaney, National Centre for Asbestos 
Related Disease, University of Western Australia pre-
sented “Mesothelin, discovery of a diagnostic marker that 
became a target”. For over fifteen years strategies have 
been pursued to target mesothelin-expressing cells using 
antibody-based therapies several of which are being 
evaluated in the clinical setting. Some of these studies 
have produced spectacular tumor regressions in some 
patients. Preliminary results of these early trials have 
been encouraging, although many different treatment 
strategies are being pursued ranging from more non-
specific immunotherapy approaches to personalized neo-
antigen vaccine development.
Pleural effusion is an underestimated and understudied 
biological matter that is minimal invasive and contains 
important disease-specific information. A conclusive 
diagnosis of both primary and metastatic tumours can 
Fig. 2 The potential of cell‑free DNA for noninvasive cancer management Plasma cell‑free circulating tumor DNA (ctDNA) analysis shows promises 
for noninvasive molecular stratification, monitoring treatment responses and identifying genetic mechanisms of resistance to guide optimal treat‑
ment strategies
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actually be based on pleural effusion cytology and bio-
marker analysis of the cell-free fraction (Fig. 3) [24]. This 
could make an earlier diagnosis possible, which in turn 
may influence the effect of chemotherapy and patient 
survival.
The molecular landscape and bio signature of vari-
ous malignancies is highly variable at this location and 
it requires detailed molecular characterisation [25–27] 
and optimized algorithms [28] to allow personalized 
treatment options and targeted therapy [29, 30]. In her 
presentation “Pleural effusion and bio-signature”, Katalin 
Dobra, Department of Laboratory Medicine, Division of 
Pathology Karolinska University Hospital in Huddinge, 
Sweden discussed their work.
Time to diagnosis by cytology versus histology in 77 
epithelioid and mixed types of malignant pleural meso-
thelioma were studied. All diagnoses were supported 
by clinical findings, including CT scans. Clinical data, 
including evaluation of responses, were retrieved from 
hospital archives and survival data were obtained from 
the Swedish population database. The results showed that 
median time for diagnosis was 1 month less for cytology 
compared to histology. Preliminary data showed that the 
proportion of patients surviving 3 years was significantly 
better (p  =  0,02) following a diagnosis based on effu-
sion cytology, among treated patients 9/26 (38 %) versus 
only 1/23 (4  %), the median survival being 23  months 
and 14 months, respectively. The rate of initial responses 
to chemotherapy (stable disease  +  partial response) 
was slightly better in the cytology group. The earlier 
MM diagnosis obtained with effusion cytology seem to 
improve the overall survival after chemotherapy. Their 
findings show the importance of the cytological diagnosis 
and encourage the initiation of treatment as soon as the 
diagnosis is obtained.
Biomarkers in tumors
From the “gold‑standard” immunohistochemistry to miR 
qISH, multi‑level molecular analyses, immune checkpoint 
markers, DNA repair and novel clinical trial designs 
for diagnosis, stratification and avoiding overtreatment
Immunohistochemistry (IHC) has traditionally been 
employed in surgical pathology as an ancillary test in the 
analysis and classification of cancers. The availability of 
antibodies to cell specific proteins, and more recently 
to organ restricted transcription factors, has improved 
the accuracy of tumor diagnoses. Increasing numbers 
of tumors are defined by their underlying molecular 
alterations identifiable by IHC. Thus, as a protein based 
technique, IHC can act as a rapid and inexpensive sur-
rogate for molecular studies. However, pre-analytical 
issues (e.g. improper tissue handling), analytical issues 
(e.g. less successful antibody clones, insufficient epitope 
retrieval, insensitive visualization systems) and post ana-
lytical issues (inconsistent reading and interpretation) 
frequently hamper the diagnostic utility of IHC.
In his talk “Immunohistochemistry in cancer diagno-
sis, the pitfalls and the future” Mogens Vyberg, Institute 
of Pathology, Aalborg University Hospital, Denmark 
explained how external quality assurance (EQA) of IHC, 
Fig. 3 Early diagnosis of malignant mesothelioma in cell rich pleural effusions. Cytomorphology is combined with adjuvant analyses comprising 
electron microscopy (left upper and left lower panels), Fluorescence in Situ Hybridization (FISH) (middle panels) and dual immunocytochemistry (right 
upper and right lower panels); distinguishing malignant cells from reactive mesothelial cells and inflammatory cells (Courtesy of Katalin Dobra)
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common definitions of controls, and digital image analy-
sis are required to improve the reliability of IHC.
More than 700 laboratories from about 85 countries are 
currently participating in the Nordic Immunohistochem-
ical Quality Control (NordiQC) [31] EQA scheme. An 
expert board has assessed more than 30,000 IHC assays 
during 2003–2015. Overall, about 20  % of the staining 
results in the breast cancer IHC module and about 30 % 
in the general module have been deemed insufficient for 
diagnostic use. The causes of unsatisfactory results have 
been identified as mainly less successful antibodies (e.g., 
insensitive clones and poorly calibrated ready-to-use 
products) and suboptimal protocols (too dilute antibod-
ies, erroneous epitope retrieval, less sensitive visualiza-
tion systems and stainer platform issues). Individually 
tailored recommendations for protocol optimization, 
description of the best tissue controls to ensure appropri-
ate calibration of the IHC assay and digital image analysis 
for HER2 stained breast cancers have generally improved 
the quality as well as inter-laboratory consistency of the 
IHC results. The increasing number of IHC assays for 
predictive markers makes continuous EQA mandatory. 
Figure 4 shows how poorly calibrated HER2 assays may 
give false negative and false positive results leading to 
erroneous patient treatment. Detailed description of the 
results of the NordiQC program is available on www.nor-
diqc.org.
Since the proposal of cancer immunosurveillance con-
cept by Burnet and Smith more than a half-century ago, 
numerous attempts of cancer immunotherapy have been 
made. Currently, immune checkpoint blockade therapy is 
revolutionizing cancer therapy, where one target is PD-1, 
originally discovered by Dr. Honjo’s group at Kyoto Uni-
versity in 1992, a TCR-coinhibitory receptor and playing 
a crucial role in the checkpoint of T-cell self-tolerance. 
One of the discoverers of the PD1 antibody and its func-
tion, Nagahiro Minato, Department of Immunology and 
Cell Biology, Graduate School of Medicine, Kyoto Uni-
versity, Japan took us through “PD-1 checkpoint block-
ade for cancer immunotherapy: History and future 
perspectives”.
In 2002, his group reported that the PD-1 checkpoint 
also takes an important role in restraining endogenous 
anti-tumor immunity, and demonstrated that the block-
ade of the PD-1 checkpoint provides a potent therapeu-
tic effect on tumors in animal models. The proposal for 
PD-1 checkpoint cancer immunotherapy was followed 
by a number of reports for beneficial effects of human-
ized anti-PD-1 or anti-PD-L1 antibodies in large-scale 
human clinical trials for various types of cancers since 
2012. FDA approved humanized anti-PD-1 antibody 
for melanoma in 2014 and for non-small and small cell 
lung cancers in 2015, and currently hundreds of clinical 
studies including various combination therapies and 
many cancer types are underway worldwide. In paral-
lel, studies on biomarkers affecting the efficacy of the 
therapy are also in progress from diverse aspects. PD-L1 
expression can be induced on cancer cells in various 
conditions, including microenvironmental stress such 
as inflammation, and irreversible genomic changes in 
cancer cells. A recent report has indicated that varying 
proportions of multiple human cancers show recurrent 
structural changes in PD-L1 gene locus at 3′ UT region, 
which leads to a remarkable increase in PD-L1 expres-
sion [32]. Somatic mutations that occur frequently in 
cancer cells may lead to the emergence of potential 
neo-antigens, particularly when cancer cells have defec-
tive mismatch-repair capacity, recruiting and activat-
ing effector T cells with additional repertoire under 
checkpoint blockade [33]. Large-scale studies under 
the support of Society for Immunotherapy of Cancer, 
for instance, have reinforced a significant prognostic 
value of immunoscore with standardized methodology 
in multiple cancers [34]. Since the effects of checkpoint 
blockade immunotherapy count on endogenous immune 
response, verification of host immune status at tumor 
sites should also provide valuable biomarkers in his talk 
the history of PD-1 discovery, basic immuno biological 
studies, and several important future perspectives on 
PD-1 checkpoint blockade cancer immunotherapy were 
discussed.
Some cancers, including melanoma, kidney, and lung 
cancer, are naturally immunogenic, and can respond to 
checkpoint inhibitor therapy (anti-CTL4 or anti-PD1/
L1). These agents block the physiologic stop signals that 
have been co-opted by tumor cells in order to evade a 
patient’s immune response. Checkpoint inhibitor block-
ade has demonstrated that a patient’s immune system 
can eliminate even widely metastatic cancer. There has 
been attention on defining the prognostic and predic-
tive power of checkpoint inhibitors. The PD-L1 pro-
tein has been explored for its prognostic and predictive 
ability, discussed by Robert A. Anders, Johns Hopkins 
University, Baltimore, USA, in his talk “Prognostic and 
predictive role of PD1 and PD-L1 in cancers”. The prog-
nostic role of PD-L1 expression in cancers is tumor type 
dependent. On the one hand PD-L1 expression indicates 
a better prognosis in melanoma and lung cancer. On the 
other hand it is a poor prognostic in gastric and kidney 
cancer. There are both technical and biologic reasons 
for these discrepancies. First, determining if a cancer 
expresses PD-L1 is complicated by the required level of 
expression, the type of cells expressing PD-L1 and the 
cellular location of PD-L1.
Second, each cancer type can have different tumor 
microenvironments.
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The predictive value of PD-L1 expression is becoming 
clearer. An early anti-PD-1 trial showed PD-L1 expres-
sion had a  ~40  % positive predictive value and a 100  % 
negative predictive value in therapeutic response to PD-1 
blockade [35]. Subsequent studies mirrored that trend 
but were not so absolute. Now PD-L1 expressing cancers 
(not broken down by tumor type) have a ~45 % chance 
of responding to therapy compared to ~15 % for PD-L1 
negative cancers [36]. PD-L1 expression on a cancer indi-
cates a patient is more likely to respond to anti-PD-L1 
blockade but should not be the single criterion for receiv-
ing therapy. Not every tumor immune microenvironment 
is identical and they are not all dependent upon PD-L1 
expression (Fig.  5). Taken together, PD-L1 is not a per-
fect biomarker for response to anti-PD1/PD-L1 therapy. 
Increasingly the integration of the type, location and 
Fig. 4 Poorly calibrated HER2 assays may give false negative and false positive results leading to erroneous patient treatment. Serial sections of a 
tissue micro array with cores from three breast ductal adenocarcinomas, marked 1, 2 and 3, stained in three laboratories marked A, B and C. Core 1 
(upper row): Carcinoma without HER2 gene amplification by FISH test and a 0/1+ immunostaining in labs A and B, while lab C obtains a 3+ staining. 
Lab C would not do a FISH test, and the patient would be offered an ineffective but costly and potentially hazardous HER2 targeted therapy. Core 
2 (middle row): Carcinoma with a low but significant HER2 gene amplification obtained 2+ immunoreaction in lab A. Lab B obtained a 1+ stain‑
ing which is false negative and the patient would not be offered HER2 targeted therapy in spite of the HER2 gene amplification. Lab C obtained a 
3+ staining but in this case it would not influence the treatment. Core 3 (lower row): Carcinoma with high HER2 gene amplification and a 3+ immu‑
noreaction obtained in lab A and C, while lab B obtained a 2+ staining. In a diagnostic setting this tumor would in lab 2 be reflexed to FISH test for 
final HER2 status, increasing costs and turnaround time. The assay in lab A (reference lab) was based on an FDA approved kit, while the assays in lab 
B and C were laboratory developed (Courtesy of Mogens Vyberg)
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function of tumor associated immune cells are important 
in determining patient response. Furthermore genomic 
data has shown that tumor cell mutational load is another 
key component of the immune response and a biomarker 
of response to immune based cancer therapy [37–40]. In 
particular genomic data from the cancer genome atlas 
(TCGA) was shown to be an independent predictive bio-
marker in response to checkpoint inhibition [41].
The role of complex cancer biomarkers was further 
discussed by Anne-Lise Børresen-Dale, Department of 
Cancer Genetics, Institute for Cancer Research, Oslo 
University Hospital The Norwegian Radiumhospital, 
Oslo, Norway in her talk “Role of multilevel molecular 
analyses in reducing over-treatment in breast cancer”. 
Several known prognostic factors are used to identify 
breast cancer patients with an unfavorable prognosis, 
such as tumor size, histological grade, hormone recep-
tor status and axillary lymph node metastasis. However, 
a large majority of early stage breast cancer patients 
with small primary tumors receive such treatment with-
out being at risk of developing recurrent disease. Thus a 
more precise stratification for treatment decisions is thus 
highly needed. A detailed characterization of the indi-
vidual breast tumors at the molecular level may improve 
individualized prognostication and treatment decisions. 
High-throughput molecular analyses of tumor tissue at 
DNA, (copy number and methylation) mRNA, miRNA, 
protein (using reverse phase protein arrays, RPPA), and 
metabolic (HR-MAS MR) levels were performed. Dr. 
Børresen-Dale’s group has explored to which extent com-
bining the various profiles derived from each level, can 
further subdivide the initially discovered PAM 50 expres-
sion subclasses [42, 43] and improve prognostic potential 
in individual patients. Combined analyses of gene regu-
lation at various levels may point to specific biological 
functions and molecular pathways that are deregulated in 
individual breast cancers and may reveal novel subgroups 
of patients for tailored therapy and monitoring [44].
Several of the molecular layers, both individually and 
combined, could split the ER positive Luminal A group, 
the most frequent subtype of breast cancer, into two 
subgroups with different survival. The identification of 
patients with low-risk Luminal A tumors using a set of 
methylation markers [45] or a set of miRNAs [46] will 
guide in selecting patients not benefitting from further 
adjuvant treatment.
Gastric cancer is the fourth most common cancer and 
the second leading cause of cancer-related death world-
wide. Chemotherapy both in resectable and advanced 
disease has only limited efficacy. There are no clinically 
validated prognostic or predictive biomarkers, and in his 
presentation “JWA and XRCC1 as predictive and prog-
nostic factors in gastric cancer”, Jianwei Zhou, Depart-
ment of Molecular Cell Biology & Toxicology, Cancer 
Center, School of Public Health, Nanjing Medical Univer-
sity, People’s Republic of China, took us through the jour-
ney of discovering the JWA and how it could be a valid 
clinical marker alone and together with XRCC1.
JWA and XRCC1 expression status in resectable gastric 
cancer cases treated with adjuvant chemotherapy com-
pared with surgery was tested in a first training cohort, 
a second testing cohort and finally in a validation cohort 
(n  =  80, 374 and 385 respectively) [47] showing that 
protein levels of both were significantly downregulated 
in gastric cancer lesions compared with adjacent non-
cancerous tissues. Low tumoral JWA or XRCC1 expres-
sion significantly correlated with shorter overall survival 
(OS) and multivariate regression analysis showed that 
low JWA and XRCC1 expression, separately and together, 
were independent negative markers of OS. Adjuvant 
Fig. 5 Expression of PD‑L1 in gastric adenocarcinoma. There is expression of PD‑L1 as detected by immunohistochemical staining (SP142) in the 
tumor infiltrating immune cells (yellow arrow) and not on the malignant adenocarcinoma cells (red *). Cell surface expression of PD‑L1 is evident on 
adenocarcinoma cells (black arrow head) in another PD‑L1 stained sample (Courtesy of Robert Anders)
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fluorouracil-leucovorin-oxaliplatin (FLO) significantly 
improved OS compared with surgery alone. However, 
this effect was evident only in the JWA or XRCC1 low 
expression group; similar effect was also observed in 
patients with fluorouracil- leucovorin-platinum (FLP) 
regimen for JWA and XRCC1. Therefore, JWA and 
XRCC1 protein expression in tumor are novel candidate 
prognostic markers and predictive factors for benefit of 
adjuvant platinum-based chemotherapy (FLO or FLP) in 
resectable human gastric carcinoma.
Further molecular analyses on the roles of JWA and 
XRCC1 were performed in cisplatin sensitive (SGC7901, 
BGC823) and resistant (SGC7901/DDP, BGC823/DDP) 
human gastric cancer cells and unraveled mechanistically 
that JWA regulated cisplatin induced DNA damage and 
apoptosis through CK2—P-XRCC1—XRCC1 pathway, 
indicating a putative target for reversing cisplatin resist-
ance in gastric cancer [48].
The first two microRNAs (miRNAs) discovered—lin-4 
in 1993 and let-7 in 2000—have critical roles in worm 
development, as loss of either results in retarded worm 
development due to lack of cell differentiation. Conse-
quently, when miRNAs were recognized as a large and 
highly conserved class of genes in 2001, scientists quickly 
surmised miRNAs potential in cancer biology. Indeed, 
cancers are characterized by altered miRNA expression 
profiles and individual miRNAs can act as oncogenes and 
tumor suppressors. In his presentation “From worm to 
man: Discovery of microRNA and current potential as 
clinical biomarkers and targets”, Pål Sætrom, Department 
of Computer and Information Science took us through 
why microRNAs are considered promising candidates 
both as cancer biomarkers and as therapeutic targets. 
To illustrate, PubMed has presently indexed more than 
60,000 papers and abstracts on miRNAs; 40  % of these 
are about cancer.
MicroRNAs are short, non-coding RNAs comprising 
18–23 nucleotides, and more than 2000 microRNAs have 
been reported in the human genome. MicroRNAs exert 
cell-specific activity by binding to the 3′UTR of mRNAs 
and thereby negatively regulating translation. The 
mature microRNAs are bound in protein complexes in 
which they are stable in tissues and blood. Most current 
therapeutic strategies aim to address tumor imbalance 
in miRNA expression and individual miRNA’s role as 
oncogene or tumor suppressor. Specifically, tumors with 
down-regulated miRNAs that are tumor suppressors are 
treated by introducing molecules that mimic miRNAs, 
whereas tumors with up-regulated oncogenic miRNAs 
are treated by introducing molecules (anti-miRs) that 
prevent the oncomirs from binding their target RNAs. 
Currently, a mimic for miR-34 is in clinical trials for liver 
cancer, whereas multiple anti-miRs are at the preclinical 
stage for different cancers [49].
Most current therapeutic strategies aim to affect miR-
NAs canonical roles in regulating protein coding genes 
post transcription in the cytoplasm. However, miRNAs 
can also regulate genes by affecting gene transcription 
in the nucleus. Others and we have shown that artifi-
cial miRNA-like RNAs, so-called short activating RNAs 
(saRNAs) can transcriptionally up-regulate target genes 
[50]. One such saRNA, targeting the transcription factor 
CCAAT/enhancer-binding protein alpha (CEBPA), can 
reduce tumor burden and improve liver function in liver 
cancer models and is currently in clinical Phase 1.
Tissue slide-based assays provide qualitative (tumor 
compartment) and semi-quantitative (expression levels) 
of miRNA expression at single-cell resolution in clini-
cal tumor specimens and show a potential prognostic 
value in urothelial carcinoma, colon, lung, breast cancer, 
melanoma and glioma [51]. However, imaging analy-
sis of microRNA expression is not in clinical use so far. 
MicroRNA-21 (miR-21) is the most prevalent microRNA 
in many tumors and regulates expression of tumor sup-
pressors like PTEN and PDCD4. In “miR-21 quantitative 
in situ hybridization and its value as biomarker in a clini-
cal setting”, Boye Schnack Nielsen, Molecular Histology, 
Bioneer A/S, Hørsholm, Denmark, presented data related 
to the performance of the miR-21 in  situ hybridization 
(ISH) using locked nucleic acid (LNA) probe technology 
[52] based on digital whole slides. miR-21 is expressed 
at increased levels in tumor tissue compared to normal 
tissue and is positively associated with poor prognosis, 
e.g. in stage II colon cancer [53]. Image analysis per-
formed on digital whole slides showed increased preci-
sion compared to previous methods (Fig. 6). The miR-21 
was primarily located in stromal fibroblast-like cells [54]. 
Moreover, miR-21 qISH expression levels were independ-
ent of tumor heterogeneity [55], which is a prerequisite 
for robust cancer biomarkers. The study concluded that 
the miR-21 qISH expression estimates, together with vis-
ual examination of the staining patterns, may prove use-
ful for better stratification of the cancer patients, and that 
the miR-21 qISH approach may work as a model system 
for microRNA qISH analyses in general.
MicroRNAs can function as predictors and prognos-
ticators in several types of cancer. For malignant pleural 
mesothelioma (MPM) prognosis is poor, but a subset of 
patients treated with multimodal treatment can have a 
long survival. However, this treatment is highly invasive 
and stressful for the patients, and there are no markers 
to predict outcome in this patient group. In “MicroRNAs 
as prognostic biomarkers for survival in surgically treated 
malignant pleural mesothelioma patients”, Michaela 
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B Kirschner, Division of Thoracic Surgery, University 
Hospital Zurich, Switzerland presented the possibil-
ity of using a microRNA expression signature as prog-
nostic factor for patients considered for multimodality 
treatment including surgical resection. This study used 
three independent series of MPM tumor samples: Series 
1–3 were samples from 48 extrapleural pneumonecto-
mies (EPP), 43 pleurectomy/decortications (P/D) and 
100 EPP with matching diagnostic biopsies respectively. 
MicroRNA expression was analyzed by RT-qPCR and 
associations with survival are assessed by Kaplan–Meier 
log-rank analysis. In addition, a microRNA expression 
signature (miR-Score) for prediction of good progno-
sis (≥20 months survival) was built using binary logistic 
regression modeling, and evaluated by receiver operat-
ing characteristics curve analysis. The miR-Score includ-
ing 6 microRNAs (miR−21, −23a, −30e, −221, −222, 
−31) was able to predict a good prognosis with an accu-
racy of 92.3 % in patients undergoing EPP and an accu-
racy of 71.9  % in patients receiving P/D. Score-positive 
patients showed increased median overall survival of 
23 and 9 months for EPP and P/D, respectively. Hazard 
ratios for score-negative patients were 4.12 (95  % CI: 
2.03–8.37, p = 0.00001) for EPP and 1.93 (95 % CI: 1.01–
3.69, p =  0.047) for P/D. Furthermore, adding the miR-
Score to a prognostic model consisting of clinical factors 
resulted in improved accuracy [56].
Further investigations on the effect of chemotherapy 
and the prognostic value of the miR-Score in series 3 are 
currently ongoing. In conclusion this study has identi-
fied a novel microRNA signature with prognostic value in 
MPM patients. Ongoing validation and refinement of the 
miR-Score has the potential to provide a novel biomarker 
for more accurate selection of MPM patients considered 
for multimodality treatment.
DNA repair is essential for cell survival and preven-
tion of mutations and cancer. In addition, DNA repair 
is intimately integrated with immunity. In “DNA Repair 
in diagnosis and therapy of cancer—opportunities and 
problems”, Hans E. Krokan, Department of Cancer 
Research and Molecular Medicine, Norwegian University 
of Science and Technology (NTNU) Trondheim, Norway, 
presented a historical overview of the DNA repair field 
an current implications. It has been known since 1968 
that DNA excision repair deficiency causes sensitivity 
to UV-light and skin cancer in Xeroderma pigmentosum 
[57]. It is now known that more common cancers can be 
caused by unrepaired DNA damage and repair deficien-
cies. Thus, inactivation of double strand break repair 
(DSBR) due to BRCA1 or 2 gene mutations results in 
defective DSBR and strongly increased risk of early onset 
breast cancer and ovarian cancer. A potential upside is 
that BRCA1/2-defective cancers are sensitive to single 
strand break repair protein poly(ADP)ribose polymerase 
(PARP) inhibitors, due to synthetic lethality [58]. DNA 
mismatch-repair deficiency similarly causes hereditary 
non-polyposis colorectal cancer and several less com-
mon other cancers, the diagnosis of which is important 
to initiate preventive measures. Glioblastoma is a deadly 
form of brain tumor that is frequently deficient in direct 
repair of O6 methyl guanine by O6-meG-DNA methyl-
transferase (MGMT). MGMT-deficient tumors are sen-
sitive to the methylating agent temozolomide (TMZ), 
whereas MGMT-overexpression causes TMZ resistance. 
Furthermore, untargeted DNA-cytosine deamination 
by AID/APOBECs causes increased genomic uracil and 
Fig. 6 MiR‑21 qISH slide processing. Sample image acquired from a digital whole slide (a) and color segmented image after pixel classification (b). 
The classification was based on the various colors identified in the stained section, e.g. the intense blue color in A (miR‑21 ISH staining) is translated 
into bright green in b. Total area calculations and relative area fractions can be obtained from the color segmented image For further details, see Erik‑
sen et al. 2016 [46] (Courtesy of Boye Schnack Nielsen)
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AID/APOBEC mutational signatures in B-cell malignan-
cies and several other types of cancer. In line with this, 
it was observed that clustered mutations (kataegis) in 
B-cell malignancies predominantly carry AID-hotspot 
mutational signatures [59]. Thus, AID/APOBEC-induced 
mutagenic U: G mismatches in DNA left unrepaired may 
be one fundamental and relatively common cause of sev-
eral malignancies.
With the availability of widespread genomic sequenc-
ing, and the introduction of specific targeted agents for 
subsets of patients with adenocarcinoma, survival for 
patients with non-squamous metastatic non-small cell 
lung cancer (NSCLC) squamous cell cancer (SCC) has 
significantly improved [60, 61]. Comprehensive genomic 
surveys, have also vastly improved our understand-
ing of the mutational profile of SCC [62]. The Cancer 
Genome Atlas Project (TCGA) extensively profiled 
178 SCC tumor specimens for genomic alterations and 
identified that TP53 was almost universally mutated in 
the tumor samples, but other genes such as CDKN2A/
RB1, NFE2L2/KEAP1/CUL3, PI3  K/AKT, and SOX2/
TP63/NOTCH1 signaling pathways were also commonly 
altered [62].
Due to the genetic diversity and lack of clear oncogenic 
drivers in this disease, there is a need to develop clinical 
trials solely focused on SCC that can evaluate single agent 
and combination targeted therapies. In “Novel Clini-
cal Trial design including biomarkers: The LUNG-MAP 
(Lung Master protocol, S1400) study”, Vassiliki Papadimi-
trakopoulou, Department of Thoracic/Head and Neck 
Medical Oncology, MD Anderson, Houston, USA, 
described the Lung-MAP (Master Protocol), an umbrella 
master multi study protocol that incorporates genomic 
testing of tumors through a next generation sequencing 
(NGS) platform (Foundation Medicine) for patients with 
SCC after progression on first line therapy (Fig. 7). This 
protocol represents partnership engaging the National 
Cancer Institute (NCI) and its Thoracic Malignancies 
Steering Committee (TMSC), the Foundation of the NIH 
(FNIH), the pharmaceutical industry, advocacy groups 
such as Friends of Cancer Research (FOCR), and the 
Federal Drug Administration (FDA). The main goal is to 
identify safe and effective regimens that match predictive 
biomarkers with targeted drugs. After genomic testing, 
patients are randomized into one of several sub-studies, 
each comparing an experimental targeted therapy with 
standard of care therapy, based on identification of can-
didate predictive biomarkers associated with each sub-
study. New trials addressing alternative targets are being 
planned and each sub-study opens and closes indepen-
dently of others. The study offers patients both targeted 
(matched sub-studies) and immunotherapy treatments 
Fig. 7 Trial Schema of the Lung‑MAP study
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(non-match), all within the umbrella master protocol 
design (schema).
Handling of multiple datasets for biomarker 
discovery and validation
Bioinformatics is one of the most important keys 
in transforming molecular data to a clinically valid test
Clinical, epidemiological, environmental, molecular, 
and genetic data related to cancer are becoming more 
and more available. A main computational analysis task 
of these data is to identify the minimal-size sets of bio-
markers and biosignatures that collectively carry all the 
information for optimal prediction or diagnosis of the 
outcome of interest (e.g., cancer stage, survival, metasta-
sis, etc.). In his talk “Automated Computational Discov-
ery of Biomarkers and Biosignatures from Data Using 
Machine Learning” Ioannis Tsamardinos, Department 
of Computer Science, University of Crete, Heraklion, 
Greece takes on his experience on biosignatures with 
these properties which provide useful insight to the 
causal mechanisms of disease or can be used for devising 
diagnostic tests of minimal cost. Computational methods 
that try to solve this problem may for example return a 
minimum set of genes and environmental factors whose 
interactions, collectively best predict metastasis. Tsamar-
dinos also presented the computational problems arising 
when trying to identify biosignatures, such as identifying 
one or all equivalent biosignatures, constructing predic-
tive models from their measurements, estimating the 
performance of the predictions, tuning the algorithms for 
optimal prediction performance, identifying anomalous 
cases (e.g., outliers), and estimating the information value 
of obtaining new samples. Finally he presented related 
computational tools, libraries, and an automated, intel-
ligent analysis pipeline for use by a non-expert that can 
perform a quality-analysis with a few clicks. The pipeline 
is demonstrated on several cancer prediction and diag-
nostic related problems.
Conclusions
Through these Symposium presentations, the plural-
ity, the various applications but also the pitfalls of cur-
rent and potential future cancer biomarkers have been 
demonstrated. The use of tumor tissue is still the gold 
standard for diagnostic, prognostic and predictive bio-
markers, including immunoscore of TILs, but circulating 
cells, tumor DNA and microRNA in blood are currently 
entering clinical practice. Multi-omics, poly-markers or 
multi-level tests may also be of high importance, as sin-
gle type of molecules rarely can be sufficient to describe 
heterogeneous tumors. Pleural fluid and urine contain 
clinically relevant biological information, exemplified in 
mesothelioma and lung cancer. Bioinformatics is key to 
analysis, discovery and validation of biomarkers. Clinical 
use of biomarkers is hampered by their variable sensitiv-
ity and/specificity due to technical/laboratory variations 
and the heterogeneity of cancer phenotypes. Analysis of 
both ready-to-use open source high-throughput data as 
the TCGA but also of large prospective biobanks as the 
HUNT will be crucial for the timely discovery of non-
invasive early diagnostic as well as predictive and prog-
nostic markers. Finally, the integration of molecular 
knowledge in clinical trials was highlighted and seems 
likely be a key point for every future clinical study.
Authors’ contributions
The Symposium excerpts were selected and summarized by ODR. Each 
presenter mentioned in the text carried the responsibility of writing their 
respective parts with their respective figures and tables and agreed to the final 
version of the manuscript. All authors read and approved the final manuscript.
Author details
1 Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, 
Bethesda, USA. 2 Department of Community Medicine, UiT The Artic University 
of Norway, Tromsø, Norway. 3 Department of Pathology and Center for Molec‑
ular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA. 
4 Department of Medical Oncology, School of MedicineUniversity of Crete, 
Heraklion, Greece. 5 National Centre for Asbestos Related Disease, University 
of Western Australia, Perth, Australia. 6 Division of Pathology, Department 
of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, 
Stockholm, Sweden. 7 Department of Clinical Medicine, Institute of Pathology, 
Aalborg University Hospital, Aalborg University, Aalborg, Denmark. 8 Depart‑
ment of Immunology and Cell Biology, Graduate School of Medicine, Kyoto 
University, Kyoto, Japan. 9 Department of Pathology, Johns Hopkins University, 
Baltimore, USA. 10 Department of Cancer Genetics, Institute for Cancer 
Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, 
Norway. 11 Department of Molecular Cell Biology & Toxicology, Cancer Center 
School of Public Health, Nanjing Medical University, Nanjing, People’s Republic 
of China. 12 Department of Computer and Information Science, NTNU, 
Trondheim, Norway. 13 Molecular Histology Bioneer A/S, Hørsholm, Denmark. 
14 Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland. 
15 Department of Cancer Research and Molecular Medicine, Norwegian Uni‑
versity of Science and Technology (NTNU), Trondheim, Norway. 16 Department 
of Thoracic/Head and Neck Medical Oncology, MD Anderson, Houston, USA. 
17 Department of Computer Science, University of Crete, Heraklion, Greece. 
18 Cancer Clinic, Department of SurgeryLevanger Hospital, Nord‑Trøndelag 
Hospital Trust, Levanger, Norway. 19 Department of Clinical Medicine, Clinical 
Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark. 
Acknowledgements
We whish to thank all sponsors and supporters of the Symposium, the 
NTNU, the HUNT Research Center, Boeringer Ingelheim, Bristol Myers Squibb, 
Norwegian Biochemical Society, Roche, Astra Zeneca, Amgen, the PROMEC of 
NTNU, International Union of Basic and Clinical Pharmacology, Gastrointestinal 
Section, the organizing committee and international faculty.
Competing interests
The authors declare that they have no competing interests.
Funding
There was no funding for writing this meeting report.
Received: 1 September 2016   Accepted: 10 October 2016
Page 14 of 15Robles et al. J Transl Med  (2016) 14:295 
References
 1. Buchbinder EI, Desai A. CTLA‑4 and PD‑1 pathways: similarities, 
differences, and implications of their inhibition. Am J Clin Oncol. 
2016;39:98–106.
 2. Lowy DR, Collins FS. Aiming high‑changing the trajectory for cancer. N 
Engl J Med. 2016;374:1901–4.
 3. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, et al. Increased 
levels of circulating interleukin 6, interleukin 8, C‑reactive protein, and risk 
of lung cancer. J Natl Cancer Inst. 2011;103:1112–22.
 4. Ryan BM, Pine SR, Chaturvedi AK, Caporaso N, Harris CC. A combined 
prognostic serum interleukin‑8 and interleukin‑6 classifier for stage 1 
lung cancer in the prostate, lung, colorectal, and ovarian cancer screen‑
ing trial. J Thorac Oncol. 2014;9:1494–503.
 5. Mathe EA, Patterson AD, Haznadar M, Manna SK, Krausz KW, et al. Nonin‑
vasive urinary metabolomic profiling identifies diagnostic and prognostic 
markers in lung cancer. Cancer Res. 2014;74:3259–70.
 6. Haznadar M, Cai Q, Krausz KW, Bowman ED, Margono E, et al. Urinary 
metabolite risk biomarkers of lung cancer: a prospective cohort study. 
Cancer Epidemiol Biomark Prev. 2016;25:978–86.
 7. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. Unique 
microRNA molecular profiles in lung cancer diagnosis and prognosis. 
Cancer Cell. 2006;9:189–98.
 8. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, et al. The association of 
microRNA expression with prognosis and progression in early‑stage, non‑
small cell lung adenocarcinoma: a retrospective analysis of three cohorts. 
Clin Cancer Res. 2011;17:1875–82.
 9. Akagi I, Okayama H, Schetter AJ, Robles AI, Kohno T, et al. Combina‑
tion of protein coding and noncoding gene expression as a robust 
prognostic classifier in stage I lung adenocarcinoma. Cancer Res. 
2013;73:3821–32.
 10. Okayama H, Schetter AJ, Ishigame T, Robles AI, Kohno T, et al. The expres‑
sion of four genes as a prognostic classifier for stage I lung adenocar‑
cinoma in 12 independent cohorts. Cancer Epidemiol Biomark Prev. 
2014;23:2884–94.
 11. Robles AI, Arai E, Mathe EA, Okayama H, Schetter AJ, et al. An inte‑
grated prognostic classifier for stage i lung adenocarcinoma based on 
mRNA, microRNA, and DNA methylation biomarkers. J Thorac Oncol. 
2015;10:1037–48.
 12. Lund E, Holden L, Bovelstad H, Plancade S, Mode N, et al. A new statistical 
method for curve group analysis of longitudinal gene expression data 
illustrated for breast cancer in the NOWAC postgenome cohort as a proof 
of principle. BMC Med Res Methodol. 2016;16:28.
 13. Pantel K, Diaz LA Jr, Polyak K. Tracking tumor resistance using ‘liquid 
biopsies’. Nat Med. 2013;19:676–7.
 14. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, et al. Analysis of 
circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 
2013;368:1199–209.
 15. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, et al. Non‑invasive 
analysis of acquired resistance to cancer therapy by sequencing of 
plasma DNA. Nature. 2013;497:108–12.
 16. Garcia‑Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, et al. Mutation 
tracking in circulating tumor DNA predicts relapse in early breast cancer. 
Sci Transl Med. 2015;7(302):302ra133.
 17. Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, et al. 
Plasma AR and abiraterone‑resistant prostate cancer. Sci Transl Med. 
2015;7:312re310.
 18. Braun S, Pantel K, Muller P, Janni W, Hepp F, et al. Cytokeratin‑positive cells 
in the bone marrow and survival of patients with stage I, II, or III breast 
cancer. N Engl J Med. 2000;342:525–33.
 19. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, et al. Predictive 
and prognostic value of peripheral blood cytokeratin‑19 mRNA‑positive 
cells detected by real‑time polymerase chain reaction in node‑negative 
breast cancer patients. J Clin Oncol. 2006;24:3756–62.
 20. Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, et al. 
Trastuzumab decreases the incidence of clinical relapses in patients with 
early breast cancer presenting chemotherapy‑resistant CK‑19m RNA‑
positive circulating tumor cells: results of a randomized phase II study. 
Ann Oncol. 2012;23:1744–50.
 21. Roe OD, Stella GM. Malignant pleural mesothelioma: history, controversy 
and future of a manmade epidemic. Eur Respir Rev. 2015;24:115–31.
 22. Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, et al. The 
established and future biomarkers of malignant pleural mesothelioma. 
Cancer Treat Rev. 2015;41:486–95.
 23. Creaney J, Dick IM, Robinson BW. Discovery of new biomarkers for malig‑
nant mesothelioma. Curr Pulmonol Rep. 2015;4:15–21.
 24. Hjerpe A, Ascoli V, Bedrossian CW, Boon ME, Creaney J, et al. Guidelines 
for the cytopathologic diagnosis of epithelioid and mixed‑type malig‑
nant mesothelioma. Complementary statement from the international 
mesothelioma interest group, also endorsed by the international acad‑
emy of cytology and the papanicolaou society of cytopathology. Acta 
Cytol. 2015;59:2–16.
 25. Sun X, Dobra K, Bjornstedt M, Hjerpe A. Upregulation of 9 genes, includ‑
ing that for thioredoxin, during epithelial differentiation of mesothelioma 
cells. Differentiation. 2000;66:181–8.
 26. Sun X, Wei L, Liden J, Hui G, Dahlman‑Wright K, et al. Molecular charac‑
terization of tumour heterogeneity and malignant mesothelioma cell 
differentiation by gene profiling. J Pathol. 2005;207:91–101.
 27. Mundt F, Johansson HJ, Forshed J, Arslan S, Metintas M, et al. Proteome 
screening of pleural effusions identifies galectin 1 as a diagnostic 
biomarker and highlights several prognostic biomarkers for malignant 
mesothelioma. Mol Cell Proteom. 2014;13:701–15.
 28. Mundt F, Nilsonne G, Arslan S, Csuros K, Hillerdal G, et al. Hyaluronan and 
N‑ERC/mesothelin as key biomarkers in a specific two‑step model to 
predict pleural malignant mesothelioma. PLoS ONE. 2013;8:e72030.
 29. Sun X, Gulyas M, Hjerpe A, Dobra K. Proteasome inhibitor PSI induces 
apoptosis in human mesothelioma cells. Cancer Lett. 2006;232:161–9.
 30. Szulkin A, Nilsonne G, Mundt F, Wasik AM, Souri P, et al. Variation in drug 
sensitivity of malignant mesothelioma cell lines with substantial effects 
of selenite and bortezomib, highlights need for individualized therapy. 
PLoS ONE. 2013;8:e65903.
 31. Vyberg M, Nielsen S. Proficiency testing in immunohistochemistry–expe‑
riences from Nordic Immunohistochemical Quality Control (NordiQC). 
Virchows Arch. 2016;468:19–29.
 32. Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, et al. Aberrant 
PD‑L1 expression through 3′‑UTR disruption in multiple cancers. Nature. 
2016;534:402–6.
 33. Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, et al. Target‑
ing of cancer neoantigens with donor‑derived T cell receptor repertoires. 
Science. 2016;352:1337–41.
 34. Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, et al. Immunoscore and 
Immunoprofiling in cancer: an update from the melanoma and immuno‑
therapy bridge 2015. J Transl Med. 2016;14:273.
 35. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, 
activity, and immune correlates of anti‑PD‑1 antibody in cancer. N Engl J 
Med. 2012;366:2443–54.
 36. Sunshine J, Taube JM. PD‑1/PD‑L1 inhibitors. Curr Opin Pharmacol. 
2015;23:32–8.
 37. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, et al. Sequen‑
tial administration of nivolumab and ipilimumab with a planned switch 
in patients with advanced melanoma (CheckMate 064): an open‑label, 
randomised, phase 2 trial. Lancet Oncol. 2016;17:943–55.
 38. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, et al. PD‑1 
blockade in tumors with mismatch‑repair deficiency. N Engl J Med. 
2015;372:2509–20.
 39. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, et al. MPDL3280A (anti‑
PD‑L1) treatment leads to clinical activity in metastatic bladder cancer. 
Nature. 2014;515:558–62.
 40. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, et al. Cancer 
immunology. Mutational landscape determines sensitivity to PD‑1 block‑
ade in non‑small cell lung cancer. Science. 2015;348:124–8.
 41. Rosenberg JE, Hoffman‑Censits J, Powles T, van der Heijden MS, Balar 
AV, et al. Atezolizumab in patients with locally advanced and metastatic 
urothelial carcinoma who have progressed following treatment with 
platinum‑based chemotherapy: a single‑arm, multicentre, phase 2 trial. 
Lancet. 2016;387:1909–20.
 42. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Molecular 
portraits of human breast tumours. Nature. 2000;406:747–52.
 43. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. Gene expression 
patterns of breast carcinomas distinguish tumor subclasses with clinical 
implications. Proc Natl Acad Sci USA. 2001;98:10869–74.
Page 15 of 15Robles et al. J Transl Med  (2016) 14:295 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 44. Kristensen VN, Lingjaerde OC, Russnes HG, Vollan HK, Frigessi A, et al. 
Principles and methods of integrative genomic analyses in cancer. Nat 
Rev Cancer. 2014;14:299–313.
 45. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, et al. 
Genome‑wide DNA methylation profiles in progression to in situ and 
invasive carcinoma of the breast with impact on gene transcription and 
prognosis. Genome Biol. 2014;15:435.
 46. Aure MR, Jernstrom S, Krohn M, Vollan HK, Due EU, et al. Integrated analy‑
sis reveals microRNA networks coordinately expressed with key proteins 
in breast cancer. Genome Med. 2015;7:21.
 47. Wang S, Wu X, Chen Y, Zhang J, Ding J, et al. Prognostic and predictive 
role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res. 
2012;18:2987–96.
 48. Xu W, Chen Q, Wang Q, Sun Y, Wang S, et al. JWA reverses cisplatin resist‑
ance via the CK2‑XRCC1 pathway in human gastric cancer cells. Cell 
Death Dis. 2014;5:e1551.
 49. Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, et al. MicroRNA thera‑
peutics: discovering novel targets and developing specific therapy. 
Perspect Clin Res. 2016;7:68–74.
 50. Meister G. Argonaute proteins: functional insights and emerging roles. 
Nat Rev Genet. 2013;14:447–59.
 51. Sempere LF. Tissue slide‑based microRNA characterization of tumors: 
how detailed could diagnosis become for cancer medicine? Expert Rev 
Mol Diagn. 2014;14:853–69.
 52. Jorgensen S, Baker A, Moller S, Nielsen BS. Robust one‑day in situ hybridi‑
zation protocol for detection of microRNAs in paraffin samples using LNA 
probes. Methods. 2010;52:375–81.
 53. Hansen TF, Kjaer‑Frifeldt S, Christensen RD, Morgenthaler S, Blondal T, 
et al. Redefining high‑risk patients with stage II colon cancer by risk index 
and microRNA‑21: results from a population‑based cohort. Br J Cancer. 
2014;111:1285–92.
 54. Nielsen BS, Jorgensen S, Fog JU, Sokilde R, Christensen IJ, et al. High 
levels of microRNA‑21 in the stroma of colorectal cancers predict short 
disease‑free survival in stage II colon cancer patients. Clin Exp Metastasis. 
2011;28:27–38.
 55. Eriksen AH, Andersen RF, Nielsen BS, Sorensen FB, Appelt AL, et al. Intratu‑
moral heterogeneity of microRNA expression in rectal cancer. PLoS ONE. 
2016;11:e0156919.
 56. Kirschner MB, Cheng YY, Armstrong NJ, Lin RC, Kao SC, et al. MiR‑score: a 
novel 6‑microRNA signature that predicts survival outcomes in patients 
with malignant pleural mesothelioma. Mol Oncol. 2015;9:715–26.
 57. Cleaver JE. Defective repair replication of DNA in xeroderma pigmento‑
sum. Nature. 1968;218:652–6.
 58. O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 
2015;60:547–60.
 59. Pettersen HS, Galashevskaya A, Doseth B, Sousa MM, Sarno A, et al. 
AID expression in B‑cell lymphomas causes accumulation of genomic 
uracil and a distinct AID mutational signature. DNA Repair (Amst). 
2015;25:60–71.
 60. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. EGF receptor gene 
mutations are common in lung cancers from “never smokers” and are 
associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl 
Acad Sci USA. 2004;101:13306–11.
 61. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. 
Activating mutations in the epidermal growth factor receptor underlying 
responsiveness of non‑small‑cell lung cancer to gefitinib. N Engl J Med. 
2004;350:2129–39.
 62. Cancer Genome Atlas Research N. Comprehensive genomic characteriza‑
tion of squamous cell lung cancers. Nature. 2012;489:519–25.
